Literature DB >> 15520781

Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis.

Claudia L Ordoñez1, Alex I Kartashov, Mary Ellen B Wohl.   

Abstract

To determine reproducibility of inflammatory marker concentrations in induced sputum from subjects with cystic fibrosis (CF), 15 nonexpectorating children, 6 to 13 years of age with mild CF lung disease, underwent 3 weekly sputum inductions with 3% saline. Neutrophil elastase concentration and bacterial cultures were reproducible. This study provides useful information for investigators designing trials of anti-inflammatory therapies in CF involving sputum induction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520781     DOI: 10.1016/j.jpeds.2004.06.054

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

Review 1.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

Review 2.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

3.  Sputum induction improves detection of pathogens in children with cystic fibrosis.

Authors:  Jordana E Hoppe; Elinor Towler; Brandie D Wagner; Frank J Accurso; Scott D Sagel; Edith T Zemanick
Journal:  Pediatr Pulmonol       Date:  2015-01-07

4.  Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: Focus on myeloperoxidase.

Authors:  Vihas T Vasu; Sharon J de Cruz; Jessica S Houghton; Keri A Hayakawa; Brian M Morrissey; Carroll E Cross; Jason P Eiserich
Journal:  Free Radic Res       Date:  2010-10-18

5.  Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling.

Authors:  Geraint B Rogers; Stuart Skelton; David J Serisier; Christopher J van der Gast; Kenneth D Bruce
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

6.  Exhaled breath condensate adenosine tracks lung function changes in cystic fibrosis.

Authors:  Charles R Esther; Bonnie M Olsen; Feng-Chang Lin; Jason Fine; Richard C Boucher
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-01-25       Impact factor: 5.464

Review 7.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

8.  Potential role of high-mobility group box 1 in cystic fibrosis airway disease.

Authors:  Steven M Rowe; Patricia L Jackson; Gang Liu; Mathew Hardison; Alessandra Livraghi; G Martin Solomon; D Brent McQuaid; Brett D Noerager; Amit Gaggar; J P Clancy; Wanda O'Neal; Eric J Sorscher; Edward Abraham; J Edwin Blalock
Journal:  Am J Respir Crit Care Med       Date:  2008-07-24       Impact factor: 21.405

Review 9.  Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.

Authors:  Geraint B Rogers; Lucas R Hoffman; Matt W Johnson; Nicole Mayer-Hamblett; Jürgen Schwarze; Mary P Carroll; Kenneth D Bruce
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

Review 10.  Novel outcome measures for clinical trials in cystic fibrosis.

Authors:  Harm A W M Tiddens; Michael Puderbach; Jose G Venegas; Felix Ratjen; Scott H Donaldson; Stephanie D Davis; Steven M Rowe; Scott D Sagel; Mark Higgins; David A Waltz
Journal:  Pediatr Pulmonol       Date:  2014-12-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.